Alnylam Pharmaceuticals (ALNY) Interest Expenses (2020 - 2026)

Alnylam Pharmaceuticals has reported Interest Expenses for 7 years, with the latest figure at $69.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 18.83% year-over-year to $69.3 million; the trailing twelve-month figure through Mar 2026 stood at $219.3 million (up 33.0% YoY), and the FY2025 full-year result was $252.6 million, up 78.08% from the prior year.
• Interest Expenses for Q1 2026 stood at $69.3 million, up from $65.4 million in the prior quarter.
• The five-year high for Interest Expenses was $69.3 million in Q1 2026, with the low at $29.0 million in Q1 2023.
• Historically, Interest Expenses has averaged $41.0 million across 5 years, with a median of $39.0 million in 2024.
• Annual changes were most pronounced in 2023 — Interest Expenses tumbled 31.65% — and 2025, when it soared 67.82%.
• Alnylam Pharmaceuticals' Interest Expenses stood at $29.9 million in 2022, then grew by 4.76% to $31.3 million in 2023, then advanced by 24.36% to $39.0 million in 2024, then surged by 67.82% to $65.4 million in 2025, then advanced by 5.94% to $69.3 million in 2026.
• The last three Interest Expenses figures came in at $69.3 million (Q1 2026), $65.4 million (Q4 2025), and $44.4 million (Q3 2025), per Business Quant data.